Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2Phase NA 1Phase 4 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 66Carboplatin 65Paclitaxel 54Magnetic Resonance Spectroscopy 45Cisplatin 45Specimen Handling 43Gemcitabine 36Docetaxel 31Bevacizumab 31Leucovorin 29Doxorubicin 29Dexamethasone 28Fluorouracil 27Pemetrexed 26Cyclophosphamide 26Oxaliplatin 24Radiation 23durvalumab 22Radiotherapy 22Letrozole 22Etoposide 22Nivolumab 21Irinotecan 21Vincristine 20Rituximab 20Capecitabine 20Taxes 19Prednisone 19Lenalidomide 19130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pluvicto × 30 days × Clear all
NCT04720157 2026-05-27

PSMAddition

Novartis

Phase 3 Active not recruiting
1,140 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡